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Abstract
Background
Chronic lymphocytic leukemia (CLL), the most common adulthood leukemia, is character-
ized by the accumulation of abnormal CD5+ B lymphocytes, which results in a progressive
failure of the immune system. Despite intense research efforts, drug resistance remains a
major cause of treatment failure in CLL, particularly in patients with dysfunctional TP53. The
objective of our work was to identify potential approaches that might overcome CLL drug re-
fractoriness by examining the pro-apoptotic potential of targeting the cell surface receptor
CD47 with serum-stable agonist peptides.
Methods and Findings
In peripheral blood samples collected from 80 patients with CLL with positive and adverse
prognostic features, we performed in vitro genetic and molecular analyses that demonstrate
that the targeting of CD47 with peptides derived from the C-terminal domain of thrombos-
pondin-1 efficiently kills the malignant CLL B cells, including those from high-risk individuals
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with a dysfunctional TP53 gene, while sparing the normal T and B lymphocytes from the
CLL patients. Further studies reveal that the differential response of normal B lymphocytes,
collected from 20 healthy donors, and leukemic B cells to CD47 peptide targeting results
from the sustained activation in CLL B cells of phospholipase C gamma-1 (PLCγ1), a pro-
tein that is significantly over-expressed in CLL. Once phosphorylated at tyrosine 783,
PLCγ1 enables a Ca2+-mediated, caspase-independent programmed cell death (PCD)
pathway that is not down-modulated by the lymphocyte microenvironment. Accordingly,
down-regulation of PLCγ1 or pharmacological inhibition of PLCγ1 phosphorylation abol-
ishes CD47-mediated killing. Additionally, in a CLL-xenograft model developed in NOD/scid
gamma mice, we demonstrate that the injection of CD47 agonist peptides reduces tumor
burden without inducing anemia or toxicity in blood, liver, or kidney. The limitations of our
study are mainly linked to the affinity of the peptides targeting CD47, which might be im-
proved to reach the standard requirements in drug development, and the lack of a CLL ani-
mal model that fully mimics the human disease.
Conclusions
Our work provides substantial progress in (i) the development of serum-stable CD47 ago-
nist peptides that are highly effective at inducing PCD in CLL, (ii) the understanding of the
molecular events regulating a novel PCD pathway that overcomes CLL apoptotic avoid-
ance, (iii) the identification of PLCγ1 as an over-expressed protein in CLL B cells, and (iv)
the description of a novel peptide-based strategy against CLL.
Introduction
Chronic lymphocytic leukemia (CLL), a human malignancy caused by an imbalance between
proliferation and programmed cell death (PCD) [1], is the most common form of leukemia in
adults. CLL is characterized by an accumulation of monoclonal B cells (CD20+, CD5+, and
CD23+) in the peripheral blood, bone marrow, and secondary lymphoid organs that leads to the
progressive failure of the immune and hematopoietic systems [2]. CLL prognosis is dependent
on clinical Rai (United States) or Binet (Europe) staging and biological markers, including IGHV
status, cytogenetic abnormalities,NOTCH1 or SF3B1mutations, and the expression of proteins
such as CD38 or ZAP70 [3–5]. Despite intense research and pharmaceutical development, CLL
remains an incurable disease. Indeed, 15%–25% of patients remain or become refractory to the
current chemotherapeutic regimes [6]. Moreover, patients with a dysfunctional TP53 gene (~7%)
require a specific aggressive therapy that often yields negative results [7]. Novel therapies target-
ing the B cell receptor (BCR)–associated kinases have recently been approved in the United
States and Europe for relapsed CLL [8,9]. However, it is still very important to develop alternative
PCD approaches that kill specifically the malignant CLL cells, including those in high-risk indi-
viduals, while sparing the residual CD5− B lymphocytes and the T cells of the CLL patient.
From this perspective, CD47 appears to be a target of high therapeutic potential in CLL.
CD47, a cell surface receptor that binds to signal regulatory protein-α (SIRPα) and thrombos-
pondin-1 (TSP1), serves as a marker of self and participates in the regulation of the cellular re-
sponses to stress [10–17]. The binding of CD47 to either SIRPα or TSP1 provides two
anticancer strategies. On the one hand, antibodies targeting CD47 or SIRPα, recombinant
SIRPα, or TSP1-derived proteins promote phagocytosis and tumor cell elimination by
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disrupting the CD47–SIRPα interaction and/or inducing Fc-dependent mechanisms or PCD
[15,17–28]. On the other hand, the binding of CD47 to 4N1K, a decapeptide derived from the
TSP1 C-terminal domain [10,16,29–31], kills tumor cells and inhibits tumor growth in vivo
[23,32–37]. Even if peptide-based strategies have so far been underused, a renewed interest in
therapeutic peptides has emerged because of advances in the development of novel tools aimed
at generating peptides that are resistant to proteolytic degradations (e.g., obtained by introduc-
tion of amino acid surrogates or non-natural amino acids) [38]. Of 340 potential therapeutic
peptides described to date, 160 (60 in phase I, 80 in phase II, and 20 in phase III) are being clin-
ically investigated. In addition, there are more than 80 approved peptides (58 are drugs and 23
are used as diagnostic agents or vaccines). Note that the overall success rate of peptide drugs
from phase I to commercial launch is approximately 25%, which is comparable to the success
rate of biologic drugs and twice as high as that of small molecules (~10%–12%) [38]. Moreover,
peptides have fewer side effects than biologics and are more cost-effective. Indeed, peptides
such as goserelin, octreotide, and lanreotide are commonly used anticancer drugs [38]. Alto-
gether, the success in the development of efficient therapeutic peptides emphasizes the medical
and pharmaceutical relevance of a peptide-based approach against CLL [6,7].
In view of the above, here we test the cytotoxic effect of serum-stable CD47 peptide agonists
in primary CLL B cells. Then, we use a complementary molecular and cell biology approach to
unravel the mechanisms regulating the PCD pathway enabled by these peptides in the malig-
nant B lymphocytes.
Methods
Patients, B Cell Purification, and Culture Conditions
The procedures in our study were in accordance with the Helsinki Declaration and were ap-
proved by the ethical committee on human experimentation at Pitié-Salpêtrière Hospital
(CPPIDF6, Paris, France). After obtaining written consent, peripheral blood was collected
from 80 patients diagnosed with CLL according to classical morphological and immunopheno-
typic criteria. These criteria include clinical Binet staging and the biological parameters IGHV
mutational status and CD38 and ZAP70 levels. Deletions of 17p13, 11q22 and 13q14 and triso-
my 12 were detected by fluorescence in situ hybridization (FISH) using the Vysis LSI p53/LSI
ATM and LSI D13S319/LSI 13q34/CEP 12 Multi-color Probe Kits (Abbott Molecular). The
functional status of TP53 was determined by flow cytometry, as previously described [39].
TP53mutations were detected using high resolution melting (HRM). The amplicons with an
abnormal HRM profile were confirmed by sequencing.
Mononuclear cells were purified from blood samples using a standard Ficoll-Hypaque gradi-
ent, and B cells were positively or negatively selected by magnetic microbeads coupled either to
an anti-CD19 monoclonal antibody (positive selection) or to anti-CD16,-CD3, and-CD14
monoclonal antibodies (negative depletion) (Miltenyi Biotech). No differences in cell death re-
sponse were encountered in positively or negatively selected cells. B lymphocytes, MEC-1, and
M210B4 bone marrow stromal cells (ATCC) were cultured in complete medium (RPMI 1640
supplemented with 10% fetal calf serum, 2 mM L-glutamine, and 100 U/ml penicillin-streptomy-
cin). In selected experiments, CLL cells were cultured in Ca2+-free medium (RPMI 1640 without
calcium, supplemented with dialyzed 10% fetal calf serum) prior to the induction of cell death.
Peptide Synthesis
Peptides were synthesized by solid-phase peptide synthesis on preloaded Fmoc-Lys(Boc)-
Wang or Fmoc-D-Lys(Boc)-Wang resins (Merck Chemicals). The syntheses were performed
on an ABI 433A peptide synthesizer (Applied Biosystems) at the 0.25-mmol scale. Peptides
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were purified by reverse phase high-performance liquid chromatography (HPLC) on an ACE
(C8, 5 μm, 300 Å, 10 mm × 250 mm) column (Waters) with a gradient elution (0.1% [v/v] TFA
in acetonitrile) in aqueous 0.1% (v/v) TFA. Homogeneous fractions were pooled and lyophi-
lized after confirming purity greater than 95% by analytical HPLC.
PKHB1, 4N1K, and 4NGG. All Nα-Fmoc amino acids (10 equiv.) were coupled after acti-
vation with HBTU (0.45 M in NMP) in the presence of DIEA (6 equiv., 2 M in NMP; 10 equiv.,
1:1). N-Fmoc deprotection was performed using piperidine (20% in NMP) and was monitored
by measuring the UV absorbance of the released N-(9-fluorenylmethyl)-piperidine group at
301 nm. PKHB1, MALDI-TOF MS: k-R-F-Y-V-V-M-W-K-k MH+ calculated: 1,383.8; MH+
actual: 1,385.3. 4N1K, MALDI-TOF MS: K-R-F-Y-V-V-M-W-K-K MH+ calculated: 1,383.8;
MH+ actual: 1,385.0. 4NGG, MALDI-TOF MS: K-R-F-Y-G-G-M-W-K-K MH+ calculated:
1,300.7; MH+ actual: 1,300.4.
Peptide Degradation Assays
4N1K or PKHB1 (10 mg/ml), diluted in a 1:4 human serum/RPMI 1640 mixture, was incubat-
ed at 37°C for different lengths of time, then mixed with ethanol and 5 ml of 1 M NaOH and
incubated at 4°C for at least 15 min to precipitate serum proteins. The supernatant was collect-
ed and injected in an HPLC system, and the soluble peptide was eluted by a linear gradient of
5% to 50% ACN (0.1% [v/v] TFA in acetonitrile) in aqueous 0.1% (v/v) TFA. The concentra-
tion of the peptide was calculated by the integration of the absorbance at 220 nm as a function
of the retention time.
Flow Cytometry
Annexin-V-APC (0.1 μg/ml; BD Biosciences) was used for the assessment of phosphatidylser-
ine exposure, propidium iodide (PI, 0.5 μg/ml) for cell viability analysis, and tetramethylrhoda-
mine ethyl ester (TMRE, 20 nM) for mitochondrial transmembrane potential (ΔCm)
quantification. PCD was recorded in a FACSCanto II (BD Biosciences) in the total population
(10,000 cells), and data were analyzed using FlowJo software. Chymotrypsin-like serine prote-
ase (serpase) or caspase cytofluorometric detection was performed with SerPase or Caspase ac-
tivity kits from Imgenex (IMI-2301 and IMI-2315). Residual and leukemic B cells from CLL
patients were discriminated from the mononuclear blood fraction by double labeling with anti-
CD19 PerCP-Cyc5.5 (clone SJ25C1; BD Biosciences) and anti-CD5-PE-Cy7 mAb (clone
L17F12; BD Biosciences). T cells from CLL patients were identified by a double anti-CD19
PerCP-Cyc5.5 and anti-CD3-PE-Cy7 (clone SK7; BD Biosciences) staining. Calreticulin cell
surface exposure was recorded with anti-calreticulin-PE (clone FMC75; Assay Designs). CD47
analysis was assessed with conjugated anti-CD47-PE (clone B6H12; BD Biosciences), P21 with
anti-P21-FITC (clone EA10; Calbiochem), and P53 with anti-P53-PE (clone DO-7; BD Biosci-
ences). A QuantiBRITE flow cytometry system (BD Biosciences) was used to assess the number
of CD47 molecules expressed on normal and CLL B lymphocytes.
Cell Death Induction and Inhibition
Wemainly used fresh CLL samples presenting low levels of spontaneous apoptosis. To induce
PCD, 1 × 106 cells/ml were treated for 2 h with PKHB1 (200 μM), 4N1K (300 μM), 4NGG
(300 μM), or an anti-CD47 monoclonal antibody (5 mg/ml, clone B6H12 in soluble or immo-
bilized conditions). To provide pro-survival microenvironment signals, CLL cells were pre-
incubated with sCD40L (5 μg/ml) and IL-4 (20 ng/ml) or co-cultured with the M210B4 bone
marrow stromal cell line (ATCC) before death was induced. To control for caspase-dependent
apoptosis, cells were incubated for 12 h with etoposide (250 μM). For the inhibition assays,
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BAPTA-AM (20 μM); BAPTA (5 mM); Ru360 (750 nM); dantrolene (40 μM); 2-aminoethoxy-
diphenyl borate (2-APB, 60 μM); U73122 (200 nM); the broad spectrum caspase inhibitors
Q-VD-OPh (QVD, 10 μM) and z-VAD-FMK (50 μM); the specific caspase inhibitors z-
DEVD-FMK (50 μM, caspase-3/7), z-LEHD-FMK (50 μM, caspase-8), and z-IETD-FMK
(50 μM, caspase-9); the serpase inhibitor TPCK (20 μM); or the fusion protein hSIRPα-Fc
(15 μg/ml) [40,41] was added 30 min before inducing PCD.
Protein Extraction and Immunoblotting
Cell fractions were lysed in 20 mM Tris-HCl (pH 7.4), 150 mMNaCl, 1% Triton X-100, and 1
mM EDTA supplemented with anti-protease and anti-phosphatase cocktails (Roche). Mito-
chondrial fraction was obtained with the help of a kit from Pierce. The protein concentration
was determined using the Bio-Rad DC kit, and 70 μg of protein was loaded in linear SDS-PAGE
gels. After blotting, nitrocellulose filters were probed with primary antibodies against CD47
(clone 2D3; eBioscience), activated caspase-3 (9661; Cell Signaling Technology), PLCγ1 (clone
D9H10; Cell Signaling Technology), PLCγ1-Y783 (2821; Cell Signaling Technology), Cox IV
(clone 1D6E1A8; Life Technologies), DRP1/DLP1 (clone 8/DLP1; BD Biosciences), and
α-tubulin (clone B-5–1–2; Sigma). Immunoreactive proteins were detected using HRP-
conjugated secondary antibodies and visualized with the ECL system (Thermo Scientific). Im-
munoblot images were acquired on a MF-ChemiBIS 4.2 (DNR Bio-Imaging Systems). PLCγ1-
Y783 was quantified using Multi Gauge 3.0 software (Fujifilm Life Sciences). The optical density
was normalized to the background and was expressed relative to the untreated cells (set at 1.0).
Electron Microscopy
CLL cells were centrifuged for 10 min at 300g. The pellets obtained were fixed at 4°C for 2 h in
2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.30), postfixed for 1 h in 1% buffered os-
mium tetroxide, dehydrated through a graded ethanol series, and embedded in Epon 812. Ul-
trathin sections were counterstained with 2% aqueous uranyl acetate for 30 min, then with lead
citrate for 10 min, and viewed under a Philips 100× electron microscope.
Ca2+ Measurement
Intracellular Ca2+ mobilization was assessed as previously described [42,43]. B cells were loaded for
30 min at 37°C with 1 μMFura2-AM and pluronic acid (both from Life Technologies) in glass bot-
tom dishes (MatTek Corporation) and washed in Ringer’s solution (145 mMNaCl, 5.4 mMKCl,
2 mMCaCl2, 1 mMMgCl2, 10 mM glucose, 10 mMHEPES, and 0.1% BSA [pH 7.5] with NaOH)
or, in particular cases, with 5 mM BAPTA. Then, the B cells were treated with PKHB1 or ionomy-
cin (maximum response) at the indicated concentrations and were excited by wavelengths of 340
and 380 nm. The fluorescence emissions of several cells were simultaneously recorded at a frequen-
cy of 1 Hz using a dual excitation fluorometric imaging system (TILL Photonics) and TILLvisION
software. Signals were computed into relative ratio units of the florescence intensity of the different
wavelengths (340/380 nm). Fluorescence values were analyzed using Origin software (OriginLab)
and were normalized to the first value according to the equation (F/F0) − 1, where F is the fluores-
cence at a specific time point and F0 is the fluorescence at time 0. The area under the curve, repre-
senting the extent of Ca2+ mobilization, was calculated for each cell and graphed.
Fibrillar and Globular Actin Assessment
The fibrillar/globular actin ratio was determined by fluorometric assessment. Excitation/
emission filters were 485/538 and 544/590 nm for Phalloidin-FITC (F-actin) and DNase-Alexa
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594 (G-actin), respectively. One unit equals the basal F-actin/G-actin ratio measured in 106 un-
treated cells. All reactions were recorded in an Infinite M1000 PRO plate reader (Tecan).
Quantitative Real-Time PCR
Total RNA was extracted from 11 normal and 50 CLL B lymphocyte samples using the Nucleos-
pin RNA II kit (Macherey-Nagel). cDNA was prepared using Superscript II reverse transcriptase
(Life Technologies). Quantitative real-time PCR (RT-PCR) was performed using TaqMan Gene
Expression Assays (Life Technologies) for CD47, PLCB1 (phospholipase C, beta 1), PLCB2 (phos-
pholipase C, beta 2), PLCB3 (phospholipase C, beta 3), PLCB4 (phospholipase C, beta 4), PLCG1
(phospholipase C, gamma 1), PLCG2 (phospholipase C, gamma 2), ITPR1 (inositol 1,4,5-trispho-
sphate receptor, type 1), ITPR2 (inositol 1,4,5-trisphosphate receptor, type 2), ITPR3 (inositol
1,4,5-trisphosphate receptor, type 3), RYR1 (ryanodine receptor 1), RYR2 (ryanodine receptor 2),
RYR3 (ryanodine receptor 3), STIM1 (stromal interaction molecule 1), STIM2 (stromal interac-
tion molecule 2), ORAI1 (calcium release-activated calcium modulator 1), ORAI2 (calcium re-
lease-activated calcium modulator 2), andORAI3 (calcium release-activated calcium modulator
3). PCR reactions were performed in triplicate using TaqMan Universal PCRMaster Mix (Life
Technologies). The products were amplified in a ViiA7 Real-Time PCR System (Life Technolo-
gies) at 60°C for 40 cycles. Data were analyzed using the comparative threshold cycle method.
The expression of GUSB or ABL [44] was utilized to normalize the data.
PLCγ1-Y783 Flow Cytometry Assessment
At various time points after PKHB1 treatment, 5 × 105 cells were fixed in ethanol and permea-
bilized in Triton X-100. Then cells were saturated in PBS + Triton X-100 + 10% FCS, incubated
with anti-PLCγ1-Y783 (Cell Signaling Technology), and detected using an anti-rabbit IgG con-
jugated with Alexa Fluor 488. The data on the entire cell population were collected on a FACS-
Canto II flow cytometer. PLCγ1-Y783 was quantified based on the mean fluorescence intensity
(MFI) for each sample.
IP3 Quantification
IP3 was measured using IP1 as a surrogate [45] with an HTRF assay (Cisbio). The assays were
performed in triplicate in 96-well plates, and the signal was quantified on an Infinite M1000
PRO plate reader (Tecan).
Vectors and Lentiviral Transduction
To down-regulate PLCγ1, we utilized two short hairpin RNAs (shRNAs) (A: CTGAGAAA-
TACGTGAACAA; B: AGTGAATGCTAGACAGAAA) and a control scrambled shRNA (ACGA-
TAGTCGGTCGATAAA). Forward and reverse oligonucleotides (Life Technologies) were
annealed and cloned into the pLVTHM lentiviral vector (Addgene 12247). Virus was produced in
293T cells after the CaCl2-mediated transient transfection of the lentiviral constructs and the pack-
aging plasmids pMD2.G and psPAX-2 (Addgene 12259 and 12260, respectively). Forty-eight
hours after the transfection, the lentiviral supernatants were harvested, clarified by filtration, and
immediately used to transduce 5 × 106 primary CLL or MEC-1 cells. At 72 h post-infection, GFP-
positive cells were sorted on a FACSVantage cytofluorimeter (BD Biosciences) to analyze PCD.
Animals
Mice were housed at the Bichat Medical School animal facility in strictly controlled, specific-
pathogen-free conditions. All experiments were performed in accordance with ARRIVE ethical
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guidelines [46] and with the approval of the French national committee on animal experimen-
tation (A74–18–01 and 7413). Unless otherwise specified, eight mice (Charles River Laborato-
ries) were used for each experiment/condition.
In the CLL-xenograft model, MEC-1 cells (3 × 106) were injected subcutaneously into
NOD/scid gamma (NSG) mice. When the tumor volume reached 100 mm3, mice received
intraperitoneal injections of PBS, PKHB1, or 4N1K (200 μg in 200 μl of PBS) once a week.
Tumor size was measured with a caliper, and tumor volume was calculated using the formula
(length × width2)/2 and expressed in cubic millimeters. Alternatively, at 28 d after the engraft-
ment, XenoLight RediJect 2-DG 750 Probe (Caliper) was injected into the retro-orbital sinus to
visualize tumor glucose uptake, which reflects cell proliferation [47]. Fluorescence was mea-
sured using an in vivo imaging system FX Pro (Kodak), and pictures were analyzed with Care-
stream Molecular Imaging software.
To determine hemoglobin levels, tumors were excised from euthanized mice, weighed, and
homogenized in PBS. After centrifugation, formic acid was added to the supernatant, and the
hemoglobin concentration was calculated based on the absorbance at 405 nm.
To assess PCD, calreticulin exposure, and PLCγ1-Y783, dissociated tumors were digested in
medium containing Liberase-TL (Roche), DNase-I (Calbiochem), and Collagenase-IV (Life
Technologies). Single-cell suspension, obtained by filtering through a 70-μM cell strainer, was
analyzed by flow cytometry.
In mice toxicity studies, we used the same injection protocol as in xenografted NSG mice.
The hematological parameters were monitored in blood drawn from the retro-orbital plexus
from either vehicle- (PBS) or PKHB1-treated wild-type mice (C57BL/6) with an MS9–5
analyzer (Melet Schloesing). Kidneys and livers (24 h after the third injection of PBS or
PKHB1) were fixed and embedded in paraffin. Paraffin sections (2–3 mm thick) of kidney and
liver were deparaffinized and rehydrated before staining with periodic acid—Schiff and
hematoxylin-eosin, respectively.
Immunohistochemistry
Tumor vessels were observed on 5-μm cryo-sections by targeting mouse CD31 protein. In
order to avoid unspecific background signal, sections were first pretreated with 0.3% H2O2 and
Avidin/Biotin (Vector labs). Then, sections were incubated with a rat anti—mouse CD31 anti-
body (clone MEC 13.3; BD Biosciences) followed by a goat F(ab0)2 anti-rat IgG(H+L)-Biotin
(3052–08; Southern Biotech). mCD31 was visualized with the Vectastain Elite ABC Kit (Vector
Labs) plus DAB chromogenic substrate (Interchim). Sections were counterstained with hema-
toxylin and mounted with ImmunoMount (Thermo Scientific).
Statistical Analysis
One-way ANOVA, Mann-Whitney tests, and Student’s t-tests were performed using Graph-
Pad Prism (GraphPad Software). Unless otherwise noted, our assessments included an equal
number of Binet Stage A and Binet Stage B/C CLL patients (Tables 1 and 2).
Results
Human Samples: Demographic and Clinical Characteristics
Peripheral blood samples from CLL patients were provided by the Hematology Department at
Pitié-Salpêtrière Hospital. A total of 80 CLL patients were selected for this study, including 29
women and 51 men, with a mean age of 73 ± 11 y (range: 46–96 y). Of these, 46 patients were
Stage A and 34 were Stage B or C according to the Binet classification, and 11 of the patients
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had a TP53 dysfunction. A more detailed description of the clinical characteristics of the CLL
patients is reported in Tables 1–3, including ZAP70 and CD38 expression, cytogenetics, and
IGHVmutational status. As a control in our experiments, peripheral blood samples from
healthy donors were provided by the French Blood Establishment (Etablissement Français du
Sang) transfusion center. In our study we included blood samples from 20 healthy donors (age
range: 20–70 y) with a gender ratio similar to that of the CLL panel.
PKHB1, a Human-Serum-Stable TSP1-Derived Peptide, Selectively
Kills Leukemic CD5+ B Lymphocytes, including Those from Individuals
with Dysfunctional TP53
To explore the potential of CD47 activation by peptide targeting in CLL, we first analyzed the
triggering of CD47 with the decapeptide 4N1K. This ligand of CD47 [10,16,29–31,48] induces
PCD in vitro in breast tumors and leukemic cells [23,34–37]. We corroborated that after only 2
h of treatment with soluble 4N1K (300 μM), 46% of the CLL cells obtained from 20 CLL patients
were Annexin-V-positive/PI-positive (Fig. 1A and 1B). In contrast to 4N1K, the negative con-
trol analogue 4NGG [35] was ineffective at inducing cytotoxicity in CLL cells. Note that, con-
trary to B6H12, the more commonly used anti-CD47 mAb [18,23] (S1 Fig), 4N1K induces PCD
in CLL cells in soluble conditions. Strikingly, 4N1K incubation had no effect on the normal B
lymphocytes isolated from eight healthy donors (Fig. 1B). The Mann-Whitney test substantiated
the significance of the different response to 4N1K observed in the malignant and the normal
B cells (p< 0.001). The specificity of soluble 4N1K to induce PCD in leukemic cells, but not in
normal B lymphocytes, led us to further investigate the therapeutic potential of this decapeptide.
The major weakness in the use of peptides as therapeutic agents is their short in vivo half-life
due to protease degradation. Using an HPLC approach, we observed that a 1-h incubation in
human serum resulted in more than 90% of the 4N1K peptide being degraded (Fig. 1C). For
that reason, we sought to improve 4N1K stability in human serum by replacing selected natural
L amino acids with their D counterparts [49]. The N- and C-terminal lysines of 4N1K, which
were introduced to improve solubility, are not related to the CD47 interaction site of the peptide
(VVMmotif) [50]. Therefore, we replaced these two terminal residues with their D analogues.
This novel decapeptide, PKHB1, was not degraded during long-term incubation in human
serum (Fig. 1C), but maintained its solubility and the ability to bind CD47 (S2 Fig). This specific
binding was validated by the disruption of the PKHB1–CD47 interaction with hSIRPα-Fc (a fu-
sion protein designed to specifically bind CD47 [40,41]), which led to the inhibition of PKHB1-
mediated PCD (S3 Fig). Finally, as was expected based on its serum stability and the improved
affinity to CD47 (Figs. 1C and S2), PKHB1 induced PCD in the CLL cells more potently than
4N1K did, in terms of both concentration level and incubation times. For example, at 2 h of
treatment with 200-μM peptides, PKHB1 induced cytotoxicity in ~49% of the CLL cells, where-
as 4N1K induced PCD in only ~25% of the leukemic B cell population (Fig. 1D and 1E).
The PCD response to PKHB1 was verified in 20 B lymphocyte samples from healthy donors
and in B cells obtained from the 80 CLL patients described above and in Tables 1 and 2. This
CLL cohort incorporated individuals with positive and adverse prognostic features, including
those with Binet Stage B and C; unmutated IGHV; positive ZAP70 and CD38 expression; 11q,
13q, or 17p deletion; or trisomy 12. We used PKHB1 at 200 μM, a concentration that resulted
in PCD responsiveness in CLL cells similar to that of 300-μM 4N1K at 2 h of treatment. With
this length of treatment, the spontaneous apoptosis of the primary normal and CLL B cells is
less than 5%. As shown in Fig. 1F, the PKHB1-treated CLL cells underwent a rapid cell viability
loss (a mean of 49%). Similar to 4N1K, PKHB1 had no effect on the B lymphocytes from
healthy donors (a mean of 5% cytotoxicity). The significance of this difference was verified by
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Fig 1. PKHB1 selectively induces cell death in leukemic B cells, including those from patients with dysfunctional TP53. (A) Cell viability measured
by Annexin-V and PI staining in normal or CLL B lymphocytes treated with 4N1K (300 μM, 2 h) or the negative control peptide 4NGG (300 μM, 2 h). The
percentages refer to Annexin-V-positive or Annexin-V-positive/PI-positive staining. (B) B cells from healthy donors (n = 8) and CLL patients (n = 20) were
treated and analyzed as in (A) and graphed. The panel of patients used here included an equal number of CLL patients with Binet Stage A and Binet Stage B/
C. Cell death refers to Annexin-V-positive/PI-positive labeling. (C) The proteolytic stabilities of 4N1K and PKHB1 were evaluated in human serum at the
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t-test (p< 0.001). More interesting from a future therapeutic perspective, 200-μM PKHB1
treatment for 2 h killed the CD5+ tumor B cells (~50% of Annexin-V-positive/PI-positive cells)
while sparing the residual CD5− B lymphocytes and T cells of the CLL patients (~5% and ~10%
cytotoxicity, respectively; Fig. 1G). Using a Mann-Whitney test, we observed that the difference
in PCD response to PKHB1 of the malignant B cells and the residual CD5− B lymphocytes and
T cells of the CLL patients is highly significant (p< 0.001). Overall, these findings suggest that
PKHB1 selectively kills the leukemic B cells.
In order to better characterize the effect of the CD47 agonist peptide PKHB1 in high-risk
CLL patients, we compared the response of cells with functional and dysfunctional TP53 (char-
acterized in S4 Fig and Table 3) to PKHB1 and the P53-dependent PCD inducer etoposide. In
cells with functional TP53, a 12-h etoposide treatment was required to provoke PCD compara-
ble to that obtained after 2 h of incubation with PKHB1. B lymphocytes with dysfunctional
TP53, which are resistant to etoposide, were killed after 2 h of incubation with PKHB1
(Fig. 2A). Thus, targeting CD47 with PKHB1 efficiently killed CLL cells, including those from
individuals with dysfunctional TP53.
Next, given that the microenvironment plays a critical role in the progression and drug resis-
tance of tumors [51,52], we analyzed whether PKHB1-mediated PCD is modulated by the pres-
ence of either bone marrow stromal cells or sCD40L and IL-4, two anti-apoptotic cytokines that
are generated by lymphoid tissues. Under these conditions, we observed that the responsiveness
of CLL cells to PKHB1 remained unchanged (Fig. 2B). In contrast, as corroborated by one-way
ANOVA (p< 0.001), the induction of PCD by etoposide was significantly diminished. These
data strongly suggest that, contrary to other forms of cell death, PKHB1-mediated cell death is
not down-regulated by the survival stimuli provided by the lymphocyte microenvironment.
PKHB1 Induces Caspase-Independent Programmed Cell Death in
Chronic Lymphocytic Leukemia Cells
We next assessed the mechanism regulating PKHB1-induced PCD in CLL cells. In contrast to
etoposide-induced caspase-dependent PCD, the features of PKHB1-induced killing—including
phosphatidylserine exposure, cell viability loss, and ΔCm disruption—were not prevented by
pre-incubation with broad spectrum or specific caspase inhibitors (Fig. 2C–E). The main effec-
tor caspase-3 remained an inactive pro-enzyme after the CLL cells were treated with PKHB1
(Fig. 2F). Thus, it seems that this CD47 peptide agonist induces caspase-independent PCD.
This result was substantiated with the help of a FAM-labeled analogue that binds to the active
site of the caspases. In contrast to etoposide triggering of cell death (~47% of positive cells),
after PKHB1 triggering, the leukemic CLL cells displayed low caspase labeling (6% of positive
cells) (Fig. 2G). Finally, as shown in Fig. 2H and 2I, PKHB1 also provoked a caspase-indepen-
dent exposure of calreticulin, a protein that enables phagocytes to efficiently engulf dead cells
[53]. Note that, in contrast to the constitutive expression of calreticulin in acute leukemia cells
and solid tumors [54], this protein was not detected on the surface of untreated CLL cells
indicated times. A mixture of peptide and human plasma was incubated at 37°C, and the kinetics of degradation was followed using HPLC. The relative
concentrations of the remaining soluble peptides were analyzed by the integration of the absorbance at 220 nm as a function of retention time. (D) Cell death,
measured as Annexin-V and PI co-positivity, was assessed as in (A) in leukemic cells treated with different concentrations of 4N1K or PKHB1. The data in
the plot are the mean ± standard deviation (SD) (n = 5). (E) After treatment with the indicated concentration of 4N1K or PKHB1 for the indicated time, cell
viability was assessed in the CLL cells using Annexin-V-positive/PI-positive staining. The data are graphed as mean ± SD (n = 6). (F) Cell death induced by
PKHB1 (200 μM, 2 h) was measured in B cells from 20 healthy donors and the cohort of 80 CLL patients described in Tables 1–3. The percentages refer to
the mean of the Annexin-V-positive/PI-positive staining. Statistical significance was analyzed with the t-test. (G) Cell death was measured as in (F) in
PKHB1-treated CD19−/CD3+ T cells (T cells), CD19+/CD5− B cells (residual B cells), and CD19+/CD5+ B lymphocytes (CLL cells) from CLL patients. The
data, which refer to Annexin-V and PI co-positivity, are presented as mean ± SD (residual and leukemic B cells, n = 20; T cells, n = 8). Unless otherwise
indicated, the statistical analyses included in this figure were performed with the Mann-Whitney test.
doi:10.1371/journal.pmed.1001796.g001
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Fig 2. PKHB1 induces calreticulin exposure and caspase-independent PCD in CLL cells. (A) PCD induced by PKHB1 (200 μM, 2 h) or etoposide (250
μM, 12 h) was measured in B cells from 30 CLL patients with functional TP53 and 11 CLL patients with dysfunctional TP53. The percentages refer to
Annexin-V-positive/PI-positive staining. (B) Cell death, measured as Annexin-V-positive/PI-positive staining, was detected in CLL cells, CLL cells incubated
with sCD40L and IL-4, and CLL cells co-cultured with the bone marrow stromal cell line M210B4 prior to treatment with PKHB1 (200 μM, 2 h) or etoposide
(250 μM, 12 h). The data are presented as mean ± SD (n = 8 patients). (C) Cell viability was determined in CLL cells that were pre-incubated with vehicle (−)
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(“control” in Fig. 2H). Thus, PKHB1 activated a caspase-independent PCD path that provoked
calreticulin exposure on the surface of the dying cells. In vivo, such exposure would be expected
to enable the dying cells to be recognized and engulfed [53].
PKHB1 Provoked Programmed Cell Death in Chronic Lymphocytic
Leukemia Cells via Endoplasmic Reticulum Stress, Ca2+ Overload, and
Mitochondrial Damage
From the above experiments, we learned that PKHB1 treatment triggers PCD in leukemic but
not in normal B lymphocytes. Interestingly, using flow cytometry and immunoblot analyses,
we did not see a correlation between PCD response to PKHB1 and the level of CD47 expression
on the cell surface of the malignant and normal B cells (Fig. 3A–C). Therefore, we searched for
the specific PCD mechanism that could be activated by PKHB1 in CLL cells, but not in normal
B lymphocytes.
The absence of caspase activation observed after CD47 peptide triggering of cell death led us
to evaluate the potential role of serpases, the F-actin cytoskeleton, and the fission protein
DRP1 in PKHB1-mediated PCD in CLL cells. These three elements are key in the regulation of
the caspase-independent cell death process induced in CLL cells by the immobilized anti-
CD47 mAb B6H12 [24,55,56]. Using a fluorochrome-labeled analogue, we corroborated that,
after PKHB1 triggering, the leukemic CLL cells activated the serpase family of proteases (~45%
of cells showed positive serpase labeling) (S5A Fig). To analyze the F-actin cytoskeleton, we
measured the intracellular F-actin/G-actin ratio (fibrillar actin = polymerized actin; globular
actin = depolymerized actin) [57] in PKHB1-treated cells. This approach showed that, similar
to the immobilized anti-CD47 mAb B6H12, PKHB1 ligation provoked actin depolymerization.
Interestingly, inhibition of the serpases by TPCK controlled actin damage (S5B Fig). These
data suggest a hierarchical relationship between serpases and F-actin depolymerization in
PKHB1-mediated PCD. Surprisingly, in contrast to the immobilized anti-CD47 mAb [55], the
presence of the cell death effector DRP1 was not observed in the mitochondria of PKHB1-
treated CLL cells (S5C Fig). Thus, it seems that PKHB1 and the immobilized anti-CD47 mAb
B6H12 induce different types of caspase-independent killing in the CLL cells.
Because morphological alterations in intracellular organelles correlate with the different
forms of PCD [58], we next performed an ultra-structural analysis of PKHB1-treated CLL
cells. We observed that PKHB1 treatment induced a significant dilation of the endoplasmic re-
ticulum (ER) in leukemic CLL cells, but not in normal B lymphocytes. Moreover, in contrast to
immobilized anti-CD47 mAb [55], no morphological changes or swelling were detected in the
mitochondria of PKHB1-treated CLL cells (Fig. 3D). Since the ER plays a key role in modulat-
ing Ca2+ mobilization [59], we considered a potential role of Ca2+ in PKHB1-mediated PCD.
This role was confirmed by pretreating CLL cells with the Ca2+ chelator BAPTA prior to
or QVD (+) and were treated with PKHB1 (200 μM, 2 h) or etoposide (250 μM, 12 h). The percentages refer to Annexin-V-positive or Annexin-V-positive/PI-
positive staining. (D) PKHB1- or etoposide-mediated cell death was evaluated by Annexin-V and PI staining in CLL cells pretreated with a panel of broad
spectrum or specific caspase inhibitors. The data, which refer to Annexin-V-positive or Annexin-V-positive/PI-positive labeling, are graphed as mean ± SD
(n = 7). (E) ΔΨm loss was induced by PKHB1 (200 μM, 2 h) or etoposide (250 μM, 12 h) in CLL cells pretreated with vehicle or QVD. The data are plotted as
mean ± SD (n = 7). (F) A representative immunoblot of activated caspase-3 is shown for the untreated (control) and PKHB1- or etoposide-treated CLL cells
pre-incubated with vehicle (−) or QVD (+). Equal loading was confirmed by α-tubulin probing. (G) B lymphocytes from a representative CLL donor were left
untreated (control) or were incubated with PKHB1 (200 μM, 2 h) or etoposide (250 μM, 12 h) before assessment of caspase activity with a FAM caspase
detection kit. The percentages refer to positive staining. (H) Calreticulin exposure was assessed in untreated (control) and PKHB1- or etoposide-treated CLL
cells. The percentages refer to calreticulin-positive cells. Note that, in the absence of α-calreticulin, the control isotype antibody yields negative results (“Neg.”
in the cytofluorometric plot). (I) Calreticulin exposure was ascertained in untreated (control) and PKHB1- or etoposide-treated CLL cells in the absence (−) or
presence (+) of the caspase inhibitor QVD. The data are presented as mean ± SD (n = 9). Statistical analyses in (A) and (B) were performed using one-way
ANOVA. NS, not significant.
doi:10.1371/journal.pmed.1001796.g002
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Fig 3. PKHB1 generates endoplasmic reticulum stress that provokes Ca2+-mediated PCD in the CLL cells. (A) CD47 expression was quantified using
flow cytometry in normal and CLL B cells. A representative cytofluorometric plot is presented. In the bar chart, CD47 was quantified based on the MFI in each
sample. The data are presented as mean ± SD (normal B cells, n = 20 healthy donors; CLL cells, n = 50 patients). (B) The cell surface expression of CD47
was quantified using a QuantiBRITE flow cytometry system. The number of CD47 molecules/cell in normal (n = 5 healthy donors) and CLL (n = 12 patients) B
cells is plotted. (C) CD47 expression in normal and CLL B lymphocytes was determined by immunoblot analysis. Equal loading was confirmed by α-tubulin
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incubation with PKHB1. As depicted in Figs. 3E and S5, this pretreatment abolished the fea-
tures characterizing PKHB1-mediated killing. A similar result was obtained by incubating CLL
cells in a Ca2+-free medium prior to treatment with PKHB1 (S5D Fig). Moreover, as corrobo-
rated by a t-test, pre-incubation with BAPTA-AM (intracellular Ca2+ chelator; p< 0.001), 2-
APB (inositol-1,4,5-triphosphate receptor [IP3R] inhibitor; p< 0.01), or dantrolene (ryanodine
receptor inhibitor; p< 0.01) significantly decreased PKHB1-mediated death (Fig. 3F). Alto-
gether, these findings suggest that PKHB1 treatment induces ER stress, which provokes Ca2+
overload and PCD in CLL cells.
Next, we compared Ca2+ mobilization in normal and CLL B lymphocytes using a fluores-
cence video-microscopy technology that analyzes the Ca2+ signal in single cells. In normal
B cells, PKHB1 triggered a classical Ca2+ signal with a rapid transient increase in intracellular
Ca2+ that then returned to baseline [59,60] (Fig. 4A, left panel, and S6A Fig, upper panels). In
CLL cells, PKHB1 incubation triggered a strong and sustained Ca2+ mobilization that did not re-
turn to basal level (Fig. 4A, right panel, and S6A Fig, lower panels). Thus, PKHB1 seems to pro-
voke a different Ca2+ mobilization in normal and leukemic cells. To determine whether the
sustained Ca2+ mobilization observed in PKHB1-treated CLL cells was the consequence of a sus-
tained Ca2+ influx or of persistent Ca2+ release from intracellular stores, we analyzed the Ca2+
mobilization generated by PKHB1 in cells incubated in a Ca2+-free medium. In PKHB1-treated
normal B lymphocytes, Ca2+ released from internal stores returned to basal levels. However, in
CLL cells, PKHB1 incubation triggered a sustained Ca2+ release from internal stores, which did
not return to basal level (Figs. 4B and S6B). Overall, these data indicate that the Ca2+ overload
observed in PKHB1-treated CLL cells appears to be the consequence of continuous liberation of
Ca2+ from the ER. Moreover, Ca2+ mobilization and PCD increased in PKHB1-treated CLL
cells in a dose-dependent manner (Figs. 4C and 1D). These results strongly support a direct link
between Ca2+ mobilization and induction of PKHB1-mediated PCD in CLL.
An important question arising from our above data is how the PKHB1-induced sustained
Ca2+ mobilization affects CLL cell viability. Because regulated Ca2+ entry into the mitochondria
is required to maintain intracellular Ca2+ homeostasis [61], we analyzed whether the sustained
Ca2+ mobilization induced by PKHB1 treatment in CLL cells affected the mitochondria. As
shown in Fig. 4D, a t-test analysis indicated that the pharmacological blockade of Ca2+ entry
into the mitochondria using the mitochondrial Ca2+ uniporter inhibitor Ru360 significantly
moderated the ΔCm loss induced by PKHB1 (49% of cells showed ΔCm loss in Ru360-untreat-
ed cells, whereas only 23% of cells pre-incubated with Ru360 presented ΔCm loss; p< 0.001),
thus preventing PCD. Therefore, it seems that treatment of CLL cells with PKHB1 induces a
Ca2+ overload that provokes PCD via mitochondrial damage.
PLCγ1 Is Over-Expressed in Chronic Lymphocytic Leukemia Cells, with
Increased Expression Correlated to Disease Progression
In order to unravel the molecular mechanism responsible for the sustained Ca2+ mobilization
leading to PCD in CLL cells—but not in normal B lymphocytes—treated with PKHB1, we per-
formed a quantitative RT-PCR analysis in normal (n = 11) and CLL (n = 50) B cells of the
major genes involved in the regulation of cellular Ca2+ homeostasis [59]. Out of the 17 different
probing. (D) Representative electron micrographs of untreated (control) or 200-μMPKHB1-treated normal and CLL B cells (2 h of treatment). The black
arrows denote the endoplasmic reticulum (ER) and the mitochondria (MT). Bar: 0.5 μm. (E) Cell death was measured in PKHB1-treated B cells (200 μM, 2 h)
from 50 CLL patients pre-incubated with vehicle or the external Ca2+ chelator BAPTA. The percentages refer to the mean of the Annexin-V-positive/PI-
positive staining. (F) Cell death was measured by Annexin-V-positive/PI-positive labeling in PKHB1-treated CLL cells (200 μM, 2 h) pre-incubated with
vehicle, dantrolene, 2-APB, or BAPTA-AM. The data are plotted as mean ± SD (n = 10). Statistical relevance was assessed with the Mann-Whitney test in (A)
and (B) and the t-test in (E) and (F).NS, not significant.
doi:10.1371/journal.pmed.1001796.g003
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Fig 4. PKHB1 treatment results in sustained Ca2+ mobilization that inducesmitochondrial damage and PCD in CLL cells. (A) Representative Ca2+
mobilization recorded in 200-μMPKHB1-treated normal (left) and CLL (right) B cells (n = 4 each). Ionomycin (Iono, 1 μM) was utilized as a control to show the
maximum response. The histograms showmean ± SD of the area under the curve (AUC) (in arbitrary units [A.U.]) (n = 12). (B) Representative Ca2+ release
from internal stores was visualized in PKHB1-treated normal (left) and CLL (right) B cells (n = 4 each) in Ca2+-free medium (plus 5 mM BAPTA). Histograms
represent mean ± SD of the area under the curve (n = 13). (C) Representative Ca2+ mobilization curves were recorded in CLL cells after treatment with
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genes tested, only PLCG1mRNA was found to be over-expressed by more than 3-fold in CLL
cells compared to normal B lymphocytes (Fig. 5A; Table 4). This difference in expression is
highly significant, as verified by t-test (p< 0.001). The immunoblot assessment depicted in
Fig. 5B corroborated the different expression of PLCγ1 in normal and CLL B cells. Because the
panel of PLCG1mRNA expression in CLL cells was quite scattered (Fig. 5A), we wondered
whether there was a correlation between the level of PLCG1mRNA and progression of the dis-
ease. The statistical t-test performed in 50 individuals with CLL indicated, with p< 0.001, that
more PLCG1mRNA is expressed in patients with advanced disease (Binet Stage B/C) than in
patients with indolent CLL (Binet Stage A) (Fig. 5C, left panel). This finding is further sup-
ported by results obtained in B cells from patients with unfavorable CLL evolution. In these pa-
tients, PLCG1mRNA was found to be over-expressed in CLL cells obtained at Binet Stage B/C
of diagnosis, compared to CLL B lymphocytes purified when the patient was diagnosed at
Binet Stage A (Fig. 5C, right panels). Altogether, these data indicate that the expression of
PLCG1mRNA could be considered a marker of CLL severity.
The Sustained Activation of PLCγ1 Controls PKHB1-Mediated
Programmed Cell Death in Chronic Lymphocytic Leukemia Cells
PLCγ1 catalyzes the formation of IP3, which binds to its receptors on the ER and, subsequently,
triggers store-operated Ca2+ release. PLCγ1 is over-expressed in CLL; therefore, the disparate
Ca2+ mobilization recorded in the PKHB1-treated normal and CLL B cells could be related to
the differential activation of PLCγ1. Measuring PLCγ1 activation by its phosphorylation at
Y783 [62], we observed that PLCγ1 was rapidly phosphorylated before returning to basal levels
in the PKHB1-treated normal B cells. However, PLCγ1-Y783 phosphorylation in the PKHB1-
treated CLL cells remained high for at least 2 h (Fig. 6A). Note that the kinetics of PLCγ1 phos-
phorylation matched the kinetics of Ca2+ response measured in the normal and CLL B cells
(Fig. 4A and 4B). Next, by measuring IP1 production in the PKHB1-treated CLL cells, we vali-
dated that the sustained PLCγ1-Y783 phosphorylation correlated with the increased catalytic
activity of the protein in the CLL B cells (Fig. 6B). Moreover, IP1 production following PKHB1
incubation was reduced using the PLC inhibitor U73122 (Fig. 6C), emphasizing the correlation
between the over-activation of PLCγ1 and the Ca2+ overload measured in CLL cells. Conse-
quently, as indicated by t-test (p< 0.01), the pre-incubation of CLL cells with U73122 prior to
PKHB1 treatment significantly decreased PCD (a mean of ~50% Annexin-V/PI co-positivity
was measured in U73122-untreated cells and a mean of ~18% in B lymphocytes pre-incubated
with U73122) (Fig. 6D).
In addition to the above pharmacological approach, we assessed the role of PLCγ1 in
PKHB1-mediated PCD in primary CLL cells using lentiviral down-regulation of PLCG1 with
two independent shRNAs. As shown in Fig. 6E, the Mann-Whitney test (p< 0.001) indicated
that the down-regulation of PLCG1 significantly diminished PKHB1-induced PCD in the pri-
mary CLL lymphocytes (~50% Annexin/PI co-positivity in control or scramble-transducted
cells and less than 20% in B lymphocytes transducted with a shRNA PLCG1). Overall, these
findings strongly support the key role of PLCγ1 in the PCDmediated by CD47 peptide target-
ing in CLL cells.
different concentrations of PKHB1. Ionomycin (1 μM) was used as a control to show the maximum response. (D) The loss of ΔΨm induced by PKHB1 (200
μM, 2 h) was measured in CLL cells pre-incubated with vehicle (−) or the mitochondrial Ca2+ uniporter inhibitor Ru360 (+). Representative cytofluorometric
plots are shown. The percentages refer to cells with low ΔΨm. The data from eight patients are presented in a plot as mean ± SD. The Mann-Whitney test was
used in (A) and (B) and the t-test in (D).
doi:10.1371/journal.pmed.1001796.g004
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Fig 5. PLCγ1 is over-expressed in CLL cells. (A) PLCG1mRNA levels were determined in normal (n = 11) and CLL (n = 50) B cells. The numbers refer to
mean PLCG1 transcript expression.GUSBmRNA expression was used to normalize the data. (B) PLCγ1 was detected by immunoblot analysis in normal
and CLL B lymphocytes. Equal loading was confirmed by α-tubulin detection. The optical density (OD) ratio represents the difference in protein expression.
The plot depicts mean ± SD (n = 3 independent blots). (C) Left: PLCG1mRNA levels measured in the normal and leukemic B cells used in (A) are shown by
the clinical Binet stage of the CLL patients. The numbers refer to mean PLCG1mRNA expression. Right: PLCG1mRNA levels measured in patients #48 and
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Treatment with PKHB1 Reduced Chronic Lymphocytic Leukemia Tumor
Burden In Vivo
Finally, we analyzed the in vivo effect of PKHB1 on the growth of MEC-1 tumors in NSG mice
[63]. MEC-1 is an established CLL cell line with dysfunctional TP53 that is resistant to etopo-
side treatment but responds to PKHB1 in exactly the same way as primary CLL cells (S7 and S8
Figs.). NSG mice were subcutaneously injected with MEC-1 cells, and the tumors were allowed
to grow for 14 d until they reached 100 mm3. The mice were then treated intraperitoneally
once a week with vehicle or PKHB1. After 2 wk of treatment, the PKHB1-treated, but not the
vehicle-treated, mice had a significantly decreased tumor growth rate (~50% tumor volume
diminution in PKHB1-treated mice compared to vehicle-treated mice; Fig. 7A, left panel, and
Fig. 7B; Mann-Whitney test, p< 0.05). However, as could be expected from the instability of
the peptide, 4N1K treatment was ineffective (Fig. 7A, right panel). No blood, liver, or kidney
toxicity was found in PKHB1-treated mice (S9 Fig). Analysis of the tumors from the PKHB1-
and vehicle-treated mice shows similar hemoglobin levels within the engrafted tumors, indicat-
ing that PKHB1 did not provoke anemia (Fig. 7C). Moreover, anti-CD31 labeling performed in
the tumors from the PKHB1- and vehicle-treated mice suggested that the decreased tumor
growth rate induced by PKHB1 was not a consequence of an anti-angiogenic effect (Fig. 7D).
Indeed, compared to mice receiving vehicle, the mice receiving PKHB1 showed significantly in-
creased levels of PLCγ1-Y783 phosphorylation (Fig. 7E), as well as enhanced calreticulin expo-
sure (Fig. 7F) and a loss of cell viability (Fig. 7G) within the engrafted tumors (Mann-Whitney
test, p< 0.001). Together, these findings strongly suggest that treatment with PKHB1 elimi-
nates CLL cells in vivo by inducing PLCγ1-mediated PCD.
Discussion
In this work we describe the targeting of CD47 by serum-stable TSP1-derived peptides as a
novel approach that could be used to broadly eliminate malignant CLL B cells. We performed
in vitro cellular and molecular biology assessments in primary CD5+ B lymphocytes obtained
from a cohort of 80 CLL patients, and we assessed, in a CLL-xenograft mouse model, the in
vivo capacity of the CD47 agonist peptides to reduce tumor burden. Our in vitro approach
shows that the CD47 peptide agonists enable a Ca2+-mediated, caspase-independent PCD
pathway that, sparing the normal T and B lymphocytes, efficiently kills CLL B cells, including
those from drug-refractory patients (e.g., with dysfunctional TP53). This PCD pathway, to our
knowledge molecularly described here for the first time, involves a sequence of events initiated
by the triggering of CD47 by serum-stable peptide agonists and the subsequent activation of
the signal transduction protein PLCγ1, an over-expressed protein in CLL. Further, PLCγ1 acti-
vation leads, by means of the second messenger IP3, to ER stress, cellular Ca
2+ overload, mito-
chondrial damage, and leukemic B cell death (Fig. 8). The in vivo data obtained in the CLL-
xenograft mouse model demonstrated that, by inducing PLCγ1-mediated, caspase-indepen-
dent PCD, the injection of CD47 agonist peptides significantly reduced tumor burden.
Strategies to Target CD47 for Chronic Lymphocytic Leukemia Treatment
A number of anticancer approaches attempting to kill tumor cells by phagocytosis, antibody-
dependent cell-mediated cytotoxicity, or PCD have relied on CD47 targeting by specific mAbs
#50 at different times. In 2010, both CLL patients were classified as having Binet Stage A, and in 2012 as having Binet Stage B/C. Note that the PLCG1
mRNA levels measured in these patients correlate with CLL progression.GUSBmRNA expression was used to normalize the data. The t-test was used in
(A) and (C), and the Mann-Whitney test was used in (B).
doi:10.1371/journal.pmed.1001796.g005
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Fig 6. PLCγ1 controls PKHB1-induced PCD. (A) PLCγ1-Y783 phosphorylation was detected at different times in the 200-μMPKHB1-treated normal and
CLL B lymphocytes. Representative flow cytometry histograms are shown. In the right panel, the plotted data are presented as MFI ± SD (n = 4). (B) IP1 was
quantified in 200-μMPKHB1-treated normal and CLL B cells at 2 h. The histogram depicts mean ± SD (n = 7). (C) IP1 generation was determined in 200-μM
PKHB1-treated CLL B lymphocytes pre-incubated with vehicle or the PLC inhibitor U73122. The data in the plot are mean ± SD (n = 5). Immunoblot analysis
confirmed that U73122 inhibited PLCγ1-Y783 phosphorylation in PKHB1-treated cells (200 μM, 2 h). Equal loading was confirmed by PLCγ1 probing.
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[15,20,64–66]. For CLL, a monoclonal single-chain variable fragment that induces PCD [27]
and a therapy that favors the disruption of the CD47–SIRPα link have been proposed [67].
This latter strategy requires the complementary use of rituximab (anti-CD20) to efficiently
eliminate tumor cells from a mice xenograft model [67]. In previous research, mainly per-
formed with an immobilized anti-CD47 mAb (B6H12), it has been reported that it is possible
to induce PCD in vitro in CLL B cells by CD47 triggering [23]. However, as reported in this
previous work and confirmed by our current data, when used in vitro in soluble conditions,
B6H12 is unable to directly induce PCD in CLL B lymphocytes [23] (S1 Fig). With this work in
mind, we developed PKHB1, a serum-stable CD47 agonist peptide that, in soluble conditions,
induces PCD in malignant CLL B cells. Moreover, we demonstrated that the stabilization of
TSP1-derived peptides against serum degradation increases both in vitro and in vivo biological
PCD activity. Overall, our findings strongly support the idea that the targeting of CD47 with
peptide agonists could offer medical advantages, such as specificity in provoking PCD in the
leukemic CD5+ B cells, no detected resistance, and a lack of microenvironment down-regula-
tion. Moreover, as opposed to therapeutic antibodies, peptides and small molecules can be syn-
thesized with a better yield and cost, are less likely to induce immune responses, and do not
accumulate in the kidney or liver, thus minimizing toxic side effects [68]. All of these character-
istics highlight the viability of the proposed peptide-based approach.
In contrast to the previously described TSP1-derived peptide 4N1K, which induces cell death
only in vitro [23,34–37], PKHB1 reduces in vivo tumor burden in a CLL mouse model. To gen-
erate our in vivo data, we used one of the few CLL-xenografted mouse models described to date
[63], a model widely used in cancer research. Although it does not recreate the physiopathology
of human CLL, this CLL-xenograft mouse model fully supports our in vitro observations, espe-
cially because, contrary to 4N1K, PKHB1 is stable and can reach the xenografted tumor. We
also observed in this mouse model that PKHB1 reduced tumor burden by inducing PLCγ1-me-
diated PCD and that PKHB1 did not induce apparent toxicity in the tumor-engrafted mice.
Mechanisms of PKHB1-Mediated Cell Death
The targeting of CD47 by peptide agonists enables a form of B cell death that, following the clas-
sification of the Nomenclature Committee on Cell Death [69], could be defined as “type
III-PCD” or “programmed necrosis.”More precisely, three main hallmarks allow us to classify
PKHB1-mediated PCD into the “programmed necrosis” group. First, the killing induced by
PKHB1 in the CLL B lymphocytes can be considered “programmed” because it activates the en-
zymatic machinery of the cell (e.g., by inducing PLCγ1 sustained phosphorylation). Second,
PKHB1 enables in the malignant B cells a caspase-independent form of PCD, and not a typical
caspase-dependent apoptotic pathway. Finally, the targeting of CD47 by PKHB1 generates bio-
chemical and morphological necrotic features—such as Annexin-V-positive/PI-positive staining
and the swelling of intracellular organelles (e.g., the ER) [23,55,69,70]—in the CLL B lympho-
cytes. As such, PKHB1-mediated cell death shares common features with the mode of PCD in-
duced by the immobilized anti-CD47 mAb B6H12 [23,24,55,56,71]. Certain biochemical
features are conserved, namely double Annexin-V-positive/PI-positive staining, activation of the
serpase family of proteases, and F-actin network disruption. In addition, both forms of PCD are
(D) Cell death was measured by Annexin-V-positive/PI-positive staining in untreated (control) and PKHB1-treated CLL cells (200 μM, 2 h) pre-incubated with
vehicle or U73122. The data are presented as mean ± SD (n = 10). (E) The effects of PLCG1 down-regulation on CD47-mediated PCD were assessed in
PKHB1-treated CLL B cells (200 μM, 2 h) transduced with scrambled shRNA (Scr) or two shRNAs targeting PLCG1 (shRNA A and B). Cell death, measured
by Annexin-V-positive/PI-positive staining, was plotted as mean ± SD (n = 6). Changes in PLCγ1 expression were observed by immunoblot analysis. Equal
loading was confirmed by α-tubulin detection. Statistical analyses were performed with the Mann-Whitney test in (B) and (E) and the t-test in (C) and (D).
doi:10.1371/journal.pmed.1001796.g006
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Fig 7. PKHB1 reduced in vivo CLL tumor burden by inducing PLCγ1 activation and PCD. (A) NSGmice were subcutaneously transplanted with MEC-1
cells. Starting 14 d after the engraftment, the mice received a weekly intraperitoneal injection of vehicle (control), PKHB1 (left panel), or 4N1K (right panel).
Tumor volume was measured using a caliper and graphed. The data are presented as mean ± SD (n = 8). In contrast to vehicle or 4N1K treatment, PKHB1
treatment significantly reduced the tumor volume. (B) In an experiment similar to (A), tumor growth was visualized by measuring glucose uptake. The color
scale indicates the fluorescence intensity. (C) The hemoglobin (Hb) concentration (n = 8 per group) was assessed in vehicle- (control) or PKHB1-treated
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marked by a dependence on input from several cellular compartments, including the mitochon-
drion. However, our data suggest that PKHB1-mediated PCD takes place in CLL cells via the in-
duction of cellular alterations that are regulated by the ER and the signal transduction protein
PLCγ1, but are independent from the fission protein DRP1, one of the major effectors of killing
mediated by anti-CD47 mAb [55]. It seems that, as a consequence of this difference, in contrast
to PCDmediated by anti-CD47 mAb, PKHB1 treatment does not provoke morphological
changes or swelling in the mitochondria of CLL cells. Therefore, PKHB1-mediated killing and
anti-CD47-mAb-induced cell death could represent alternate outcomes of a similar necrotic
tumors. The bars indicate the mean of the data obtained. (D) Tumor vascularity was investigated by immunohistochemistry analysis of mCD31.
Representative photographs and visual quantification of microvessel density (right panel) confirmed similar vascularity in tumors from vehicle- and PKHB1-
treated mice. The data are presented as mean ± SD. (E) PLCγ1-Y783 phosphorylation was assessed in tumors obtained from vehicle- (control) and PKHB1-
treated mice. Phospho-PLCγ1 was quantified by flow cytometry using MFI. The data are presented as mean ± SD (n = 6). (F) Calreticulin exposure was
assessed in tumors from vehicle- (control) and PKHB1-treated mice and graphed. The data are presented as mean ± SD (n = 6). (G) Percentage of cell death
was measured by Annexin-V-positive/PI-positive staining in tumors obtained from vehicle- (control) and PKHB1-treated mice. The data are plotted as mean ±
SD (n = 8). The statistical analyses included in this figure were performed with the Mann-Whitney test. A.U., arbitrary units; NS, not significant.
doi:10.1371/journal.pmed.1001796.g007
Fig 8. Schematic representation of CD47-mediated PCD in CLL cells.CD47 ligation by the agonist peptide PKHB1 (1) leads to activation of the over-
expressed second messenger PLCγ1 by phosphorylation at Y783 (2). PLCγ1-Y783 cleaves phosphatidylinositol 4,5 bisphosphate (PIP2) into inositol 1,4,5-
trisphosphate (IP3) (3), which binds IP3Rs in the ER to provoke Ca
2+ release (4). The increased intracellular Ca2+ concentration activates the ER RYRs (5).
The decrease of Ca2+ in the ER results in the opening of store-operated Ca2+ channels in the plasmamembrane, provoking substantial calcium entry into the
cell (6). This high Ca2+ concentration provokes serpase activation, actin depolymerization, and mitochondrial damage (7), followed by PCD (8).
doi:10.1371/journal.pmed.1001796.g008
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PCD pathway. The relationship between PKHB1-mediated PCD and other ways to induce PCD
by CD47 triggering [27]—which seem to implicate the activation of BNIP3/Hif or the opening of
the mitochondrial permeability transition pore—needs to be evaluated in more specific work.
In deciphering how the CD47 agonist peptide triggers PCD, we found that PKHB1 pro-
voked Ca2+ overload. The regulation of Ca2+ homeostasis within hematopoietic cells is crucial
for their function and fate [72]. According to the current model, Ca2+ influx is the result of the
membrane-receptor-mediated production of IP3 following the activation of PLC, which binds
to specific receptors on the ER membrane and provokes a quick release of internal Ca2+ that is
followed by extracellular Ca2+ entry through a process known as store-operated Ca2+ entry.
This Ca2+ signaling is transient and controlled, mainly by Ca2+ re-sequestration into the mito-
chondria and ER [73]. Our assessment of the intracellular Ca2+ influx after CD47 peptide trig-
gering suggested a totally different pattern of Ca2+ mobilization between normal and leukemic
B cells. Although the Ca2+ influx was rapidly controlled in normal B cells, we recorded a mas-
sive and sustained Ca2+ mobilization in CLL cells. In these malignant B lymphocytes, the Ca2+
overload was due to sustained activation of PLCγ1. This mechanism of PCD induction, de-
scribed here to our knowledge for the first time in primary B cells, is very similar to that previ-
ously reported for Fas-mediated apoptosis in Jurkat T cells [74].
New Roles for PLCγ1 in Programmed Cell Death and Chronic
Lymphocytic Leukemia
Together with other characteristic CLL molecules, such as CD5 or ZAP70, the function of
PLCγ1 is mainly associated with the T cell lineage. Indeed, PLCγ1 is critical for T cell function,
whereas PLCγ2 is more relevant in platelets, natural killer cells, B cells, and mast cells [75]. In T
cells, PLCγ1 is activated downstream of the T cell receptor by a large panoply of SRC, SYK, and
TEC kinases. Among them, the SYK-related kinase ZAP70 phosphorylates LAT and SLP76,
two adaptors that are critical for PLCγ1 activation. In B cells, cross-linking the BCR results in
tyrosine phosphorylation and the activation of PLCγ2 rather than PLCγ1. The SRC, SYK, and
TEC kinases also play relevant roles in PLCγ2 activation, which is essential for B cell survival
[76]. Related to CLL, IgM—BCR engagement triggers the phosphorylation of SYK, the activa-
tion of PLCγ2, and intracellular calcium mobilization [77]. Moreover, some reports have found
PLCγ2 to be over-expressed in CLL [78]. In spite of that, our shRNA down-regulation approach
indicates that, in PKHB1-mediated PCD, PLCγ1 is the key effector. This original result opens
the way to further molecular and cell biology studies. As such, it will be interesting to search for
the molecular link between CD47 triggering and PLCγ1-Y783 phosphorylation. As CD47 does
not possess tyrosine‐based activation motifs, we hypothesize that the phosphorylation of
PLCγ1 after CD47 triggering results from the association of CD47 with other counter-receptors.
This association would generate a signalization complex able to (i) activate SRC, SYK, and/or
other TEC-related tyrosine kinases and (ii) recruit/phosphorylate PLCγ1. Thus, future work
should analyze whether PLCγ1 over-expression plays a role in CLL survival; whether ZAP70 or
other SRC, SYK, and TEC kinases are implicated in the sustained PLCγ1-Y783 phosphorylation
observed after CD47 peptide triggering; and whether a direct relationship exists between CD47
and BCR or, as in other cell types [79,80], between CD47 and integrins.
Our present study not only highlights a novel PCD role for PLCγ1, but also reveals that
PLCG1mRNA expression correlates with CLL progression. Even if additional work correlating
PLCG1mRNA expression level with other CLL prognostic markers (more than 35 have been
described to date) is necessary to confirm the clinical value of these findings, our results indi-
cate that PLCG1mRNA expression could be a suitable candidate for further consideration as a
prognostic marker in CLL.
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Clinical Potential for CD47 Targeting
Deficiencies in the PCD program are frequently involved in tumor drug resistance [81]. The
design of novel strategies that bypass this blockade is a major challenge in PCD research. In re-
cent years, most PCD-based pharmacological therapies have focused on the caspase-dependent
mode of PCD, also known as apoptosis. In CLL, malignant B cells exhibit alterations that make
them resistant to this form of cell death (e.g., ATM/P53 inactivation or over-expression of the
anti-apoptotic proteins MCL1 or BCL2). However, there are alternative caspase-independent
forms of PCD that could be used to eliminate CLL cells [23,24,55]. Our experiments indicated
that the binding of CD47 by the peptide agonists provokes caspase-independent PCD with a
broad efficacy (e.g., it is effective even in cells with caspase-dependent PCD blockade). There-
fore, the induction of PCD by CD47 peptide targeting overcomes the apoptotic avoidance that
is characteristic of CLL.
Limitations and Strengths
One of the main limitations of our study is the only moderate affinity of the TSP1-derived pep-
tides to CD47. As a consequence, (i) the induction of PCD in primary CLL B lymphocytes was
achieved only at a micromolar concentration, still distant from the standard requirements in
drug development (nanomolar range), and (ii) the reduction in tumor burden in our CLL-
xenograft mouse model was limited. However, based on our original results on peptide serum
stability, we may anticipate that a second set of CD47 peptide agonists will be generated with
better efficacy and/or bioavailability than PKHB1 (e.g., obtained by introduction of amino acid
surrogates). In addition, it is generally agreed that the current CLL animal models do not fully
mimic the situation in humans. Our in vivo studies were based on one of the previously de-
scribed CLL-xenografted mouse models [63]. This model involves xenotransplanting MEC-1
cells as a solid mass in NSG mice. Given that CLL is a disseminated disease, our mouse model
does not strictly recapitulate CLL features. Consequently, we cannot rule out the possibility
that the CD47 peptide agonists might behave differently in CLL patients. Thus, complementary
preclinical and toxicological studies in more appropriate animal models (e.g., novel CLL
mouse models or primates) will be necessary before the therapeutic effect of PKHB1 and deriv-
atives can be fully assessed in humans. Finally, although PLCγ1 over-expression was clearly ob-
served in CLL B cells, the mRNA assessment of PLCG1 was done using samples from 50 CLL
patients and 11 healthy donors, which is not enough to determine whether this protein could
be considered as a prognostic marker in CLL. A more specific study, with a higher number of
samples, correlating PLCG1mRNA expression level with other CLL prognostic markers will be
necessary to verify the clinical value of our findings.
Our work presents several strengths. First, it is a translational study with three parts: (i) gen-
eration of PKHB1 (a serum-stable CD47 peptide agonist), (ii) analysis of the biological activity
of PKHB1 in vitro on a panel of primary B lymphocytes that reproduced the diversity of CLL
patients and incorporated the cytogenetic abnormalities that are associated with CLL refracto-
riness, and (iii) an in vivo approach to assess the effect of PKHB1 on a CLL mouse model,
which revealed that this peptide reduces tumor burden without apparent side effects. Second,
from a mechanistic point of view, our work reveals the existence of a Ca2+-mediated, caspase-
independent PCD signaling pathway in the tumor cells that could be enabled independently
from the classical apoptotic path (e.g., in cells with dysfunctional TP53) and that is not down-
modulated by the lymphocyte microenvironment. This mode of PCD efficiently and specifical-
ly targets malignant cells. Finally, in investigating the molecular determinants regulating
PKHB1-mediated killing, we uncovered an unexpected role for PLCγ1 in PCD and revealed a
potential link between PLCG1mRNA expression and CLL severity. Both within the CLL field
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and in the broader scope of cancer research, our mechanistic results regarding caspase-inde-
pendent PCD and PLCγ1 pave the way for the development of novel pharmacological tools
that could circumvent the chemotherapy resistance characterizing CLL cells.
Conclusions
Patients with heavily treated and refractory CLL face a critical medical need that is still unmet.
The standard front-line therapy against this leukemia (fludarabine, cyclophosphamide, and
rituximab), as well as the current alternative treatments (e.g., anti-CD52, optimized anti-CD20,
and anti-CD23 antibodies), can generate refractoriness or undesirable side effects [6]. Recently
approved in the United States and Europe, PI3K delta and Bruton tyrosine kinase (BTK) inhibi-
tors represent novel anti-CLL approaches that yield apparent durable remission in patients with
relapsed or refractory CLL. Yet, the establishment of PCD approaches such as our peptide-
based cell death strategy remains of great interest. Our strategy (i) is less expensive to produce,
(ii) is specific to the tumor cells (sparing the residual CD5- B lymphocytes and T cells of the pa-
tient), (iii) could be broadly used in CLL patients with high-risk genetic lesions, (iv) is not
down-regulated by the lymphocyte microenvironment, and (v) does not provoke apparent ane-
mia or toxicity in a CLL mouse model. Overall, our work represents a first step toward the de-
velopment of a new peptide-based treatment for CLL, which still remains an incurable disease.
Supporting Information
S1 Fig. Immobilized, but not soluble, CD47 mAb induces PCD in CLL. Cell viability mea-
sured in CLL B lymphocytes left untreated or incubated for 2 h with CD47 mAb (5 μg/ml,
clone B6H12) in soluble or immobilized conditions. The percentages refer to Annexin-V-posi-
tive or Annexin-V-positive/PI-positive staining. The cytofluorometric data from a representa-
tive CLL patient are shown. This experiment has been done ten times, yielding low
interexperimental variability (<5%).
(TIF)
S2 Fig. Primary structure of 4NGG, 4N1K, and PKHB1. In 4NGG, the two central valines of
4N1K were replaced by glycines (highlighted in red). In PKHB1, the N- and C-terminal lysines
of 4N1K were replaced with their D counterparts (highlighted in green). The dissociation con-
stants (Kd) of 4NGG, 4N1K, and PKHB1 to CD47—determined by fluorescence polarization,
isothermal titration calorimetry, and microscale thermophoresis binding assays [82]—are
1,000,000 nM, 1,500 nM, and 400 nM, respectively.
(TIF)
S3 Fig. Disruption of PKHB1–CD47 interaction with the fusion protein hSIRPα-Fc inhib-
its PKHB1-mediated PCD. Cell viability was determined in CLL cells that were pre-incubated
with vehicle (−) or hSIRPα-Fc (+) and were treated with PKHB1 (200 μM, 2 h). The percent-
ages refer to Annexin-V-positive/PI-positive. The data are graphed as mean ± SD (n = 5). The
statistical analysis included in this figure was performed with the t- test.
(TIF)
S4 Fig. Flow cytometry analysis of P53 and P21 in CLL B cells. The functional status of TP53
was determined based on the induction of P53 and P21 protein expression by etoposide in
combination with nutlin-3a [39]. The upper panels provide representative cytofluorometric
plots of P53 in CLL cells from patient #22 (functional TP53, Table 1) and patient #71 (dysfunc-
tional TP53, 96% deletion of 17p; Tables 2 and 3). In a similar experiment, the lower panels de-
pict representative plots of P21 expression in B cells from the same individuals as above.
(TIF)
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S5 Fig. PKHB1-mediated cell death and anti-CD47-mAb-induced PCD represent alternate
outcomes of a similar cell death pathway. (A) Left: B lymphocytes from a representative CLL
donor were left untreated (control) or were incubated for 2 h with immobilized CD47 mAb
(B6H12) or PKHB1 (200 μM) before assessment of serpase activity with a green fluorescent Ser-
Pase kit (FFCK). The percentages refer to positive staining. Right: B cells from CLL patients
(n = 5) were left untreated (control), were incubated with PKHB1 (200 μM, 2 h), or were pre-incu-
bated with the external Ca2+ chelator BAPTA prior to PKHB1 treatment. The data are presented
as mean ± SD. (B) CLL cells were exposed to vehicle (control), immobilized CD47 mAb (B6H12,
2 h), or PKHB1 (200 μM, 2 h), and the fluorescence F-actin/G-actin ratio was quantified. One
unit refers to the basal F-actin/G-actin ratio scored in control cells. Data are the mean of five inde-
pendent experiments ± SD. (C) B lymphocytes from a representative CLL donor were left untreat-
ed (control) or were incubated for 2 h with either immobilized CD47 mAb (B6H12) or PKHB1
(200 μM) before immunoblot detection of DRP1 in the mitochondrial fraction. Equal loading was
confirmed by Cox IV probing. (D) Cell death was measured by Annexin-V-positive/PI-positive
staining in PKHB1-treated CLL B cells (200 μM, 2 h) pre-incubated with vehicle, the external
Ca2+ chelator BAPTA, or Ca2+-free medium (n = 5). The data are graphed as mean ± SD.
(TIF)
S6 Fig. Ca2+ imaging in PKHB1-treated normal and CLL B cells. Normal B cells from a
healthy donor and B lymphocytes from a representative CLL patient were stained with Fura2-
AM and pluronic acid in glass bottom dishes. The cells were treated with PKHB1 (200 μM)
and imaged using a dual excitation fluorometric imaging system for the indicated time. Cyto-
solic Ca2+ variations were recorded in the presence of 2 mM Ca2+ (A) or 5 mM BAPTA (B).
The scale bar depicts the relative Ca2+ intensity.
(TIF)
S7 Fig. PKHB1 induces Ca2+-mediated, caspase-independent PCD in MEC-1 cells. (A)
MEC-1 cells were left untreated or were incubated for 2 h with PKHB1 (200 μM) or for 12 h
with the P53-dependent cell death inducer etoposide (250 μM); the cells were then labeled with
Annexin-V and PI to assess cell viability. The percentages refer to Annexin-V-positive or
Annexin-V-postsitive/PI-positive staining. (B) MEC-1 cells were incubated as in (A) and
stained with TMRE, and ΔCm was determined by flow cytometry. The percentages refer to
cells with ΔCm loss. As depicted in (A) and (B), the dysfunctional TP53MEC-1 cell line was re-
sistant to etoposide (12 h of treatment). (C) Cell death was measured by Annexin-V-positive/
PI-positive labeling in untreated (control) or PKHB1-treated MEC-1 cells (200 μM, 2 h) pre-
incubated with vehicle (−) or the ER receptor inhibitors dantrolene or 2-APB. The data are pre-
sented as mean ± SD (n = 6). (D) As described in (C), cell death was measured in untreated
(control) or 200-μM PKHB1-treated MEC-1 cells pre-incubated with vehicle (−) or the intra-
cellular Ca2+ chelator BAPTA-AM. The data, which refer to Annexin-V and PI co-positivity,
are mean ± SD (n = 5). (E) A representative Ca2+ mobilization triggered by 200 μM PKHB1 in
MEC-1 cells is illustrated. Ionomycin (Iono, 1 μM) was used as a control to demonstrate the
maximum response. The data are presented as mean ± SD (n = 26 cells). The statistical analysis
included in this figure was performed with the t-test.
(TIF)
S8 Fig. PLCγ1-Y783 phosphorylation controls PKHB1-induced killing in MEC-1 cells. (A)
At the indicated time, PLCγ1-Y783 phosphorylation was determined in 200-μMPKHB1-treated
MEC-1 cells using flow cytometry. (B) IP1 was quantified in MEC-1 cells left untreated or treat-
ed with PKHB1 (200 μM, 2 h). The histogram depicts mean ± SD (n = 5). (C) Cell death was an-
alyzed by Annexin-V-positive/PI-positive staining in untreated (control) and PKHB1-treated
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MEC-1 cells (200 μM, 2 h) pre-incubated with vehicle (−) or the PLC inhibitor U73122. The
data are presented as mean ± SD (n = 5). (D) The effects of the down-regulation of PLCγ1 on
PKHB1-mediated PCD (200 μM, 2 h) were determined in MEC-1 cells transduced with scram-
bled shRNA (Scr) or two shRNAs against PLCG1 (shRNA A and B). Cell death, measured by
Annexin-V-positive/PI-positive staining, was plotted as mean ± SD (n = 5). (E) A representative
Ca2+ mobilization is illustrated for 200-μMPKHB1-treated cells transduced as described in (D).
Ionomycin (1 μM) was used as a control to demonstrate the maximum response. The data are
presented as mean ± SD (scrambled shRNA, n = 29 cells; shRNA A, n = 38 cells; shRNA B, n =
33 cells). The statistical analysis included in this figure was performed with the t-test.
(TIF)
S9 Fig. PKHB1 shows no toxic effect in NSG or C57BL/6 mice. (A) Histological analysis of
kidney and liver fromNSGmice assessed after the third weekly intraperitoneal injection of vehicle
(control) or PKHB1 (10 mg/kg). Two representative liver and kidney images are shown (#1 and
#2). Liver sections were stained with hematoxylin-eosin, and kidney sections with periodic acid—
Schiff. (B) During 3 wk, C57BL/6 mice received a weekly intraperitoneal injection of vehicle (con-
trol) or PKHB1 (10 mg/kg). Mice blood was examined before (−) and 24 h post-injection in a
MS9–5 hematological analyzer, and percentages of lymphocytes, monocytes, and neutrophils, as
well as the levels of red blood cells, platelets, and hemoglobin, were assessed. Data obtained from
vehicle- (white bars) and PKHB1-treated (black bars) mice are plotted as mean ± SD (n = 6). (C)
Histological analysis of kidney and liver from C57BL/6 mice after the third weekly intraperitoneal
injection of vehicle (control) or PKHB1 (10 mg/kg). Two representative liver and kidney images
are shown (#1 and #2). Liver and kidney sections were stained as in (A). Compared to vehicle, no
sign of toxicity or tissue necrosis was observed in PHKB1-treated NSG or C57BL/6 mice.
(TIF)
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Table 1. Features of CLL patients with clinical Binet Stage A.
Patient Number IGHV Mutational Status ZAP70 CD38 FISH Karyotype
Del 17p Del 11q Del 13q Trisomy 12
1 M − − − − +mono[99/200] − nd
2 M − − − − − − Normal
3 M − − − Failure +mono[109/200]/bi[9/200] +[36/600] nd
4 M − + − − − +[106/200] nd
5 UM + − − − +mono[24/200] − Normal
6 UM + − − +[163/200] +mono[38/200] − 1 abnormality
7 UM + − − − − − Failure
8 M − − − − +bi[175/200] − nd
9 M − − − − +mono[48/200] − Normal
10 M − − − − +mono[62/200]/bi[99/200] − Normal
11 UM + + − − − − 1 abnormality
12 M − − − − +mono[78/200]/bi[23/200] − Normal
13 UM + − − +[79/200] − − Failure
14 M − − − − − − nd
15 M − − − − +mono[194/200] − nd
16 M − − − − +mono[110/200] − Normal
17 M − − − − +mono[177/200] − 1 abnormality
18 M − − − − +mono[44/200]/bi[140/200] − Normal
19 M − − − − − − Normal
20 M + − − − − − nd
21 M − − − − +mono[137/200] − 2 abnormalities
22 M − − − − − − nd
23 M − − − − − − Complex
24 M − − − − +mono[138/200] − nd
25 UM + + +[46/200] − +mono[28/200] − Complex
26 M − − − − − − Normal
27 M − − − − +mono[174/200] − nd
28 M − − − − +mono[159/200] − nd
29 M + + − − +mono[118/200] +[143/200] nd
30 M − − +[107/200] − +bi[165/200] − Complex
31 M − Nd − − − − nd
32 M − − − − +mono[133/200] − nd
33 M − − − − +mono[102/200] − Normal
34 M − + − − − − nd
35 M Grey zone − − − +mono[25/200] − nd
36 M − − − − +mono[126/200] − 1 abnormality
37 M − − − − +mono[164/200] − nd
38 UM + − − − − − Normal
39 M − − − − − − Normal
40 UM + − − − − − Normal
41 M − Nd − − +mono[32/200] − nd
42 M − − − − +mono[147/200]/bi[6/200] − 1 abnormality
43 M − − − − +mono[191/200] − Failure
44 M − − − − +mono[73/200]/bi[94/200] − 1 abnormality
45 UM + + − +[88/200] +mono[179/200] − Complex
(Continued)
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Table 1. (Continued)
Patient Number IGHV Mutational Status ZAP70 CD38 FISH Karyotype
Del 17p Del 11q Del 13q Trisomy 12
46 UM − − − +[189/200] +bi[185/200] − 1 abnormality
IGHV mutational status homology  98%: M, mutated; UM, unmutated. ZAP70 is considered negative when the ratio (R) of mean ﬂuorescence of T
lymphocytes/mean ﬂuorescence of CLL B lymphocytes  12. ZAP70 is considered positive if R  10, and “grey zone” if 10 < R < 12. CD38 is considered
positive when the percentage of positive leukemic cells is 30%. FISH: score of interphasic cells with an abnormality. Complex karyotype is 3
chromosomal abnormalities. bi, biallelic; Del, deletion; mono, monoallelic; nd, not done.
doi:10.1371/journal.pmed.1001796.t001
Table 2. Features of CLL patients with clinical Binet Stage B/C.
Patient Number IGHV Mutational Status ZAP70 CD38 FISH Karyotype
Del 17p Del 11q Del 13q Trisomy 12
47 UM + + − +[174/200] +mono[193/200] − Normal
48 M − − − − − − Normal
49 M − − − +[111/200] +mono[170/200] − nd
50 M − − − − +mono[93/200] − Failure
51 UM + − − − − − Failure
52 UM Grey zone + − +[176/200] +mono[43/200] − 1 abnormality
53 UM − − +[178/200] − +mono[20/200] − Complex
54 UM + − − +[45/200] +mono[83/200] − Complex
55 M − + − − +bi[166/200] − Normal
56 M − + − − − − 1 abnormality
57 UM + − − − +mono[200/200] − 1 abnormality
58 M − − − − +mono[165/200] − 1 abnormality
59 M − − +[34/200] − +mono[15/200]/bi[171/200] − Failure
60 UM + − − − +mono[180/200] − Normal
61 UM + + − +[149/200] +mono[146/200] − Complex
62 M − − +[195/200] − +mono[193/200] − Complex
63 UM + + − +[181/200] − − 1 abnormality
64 UM + − − − − − Normal
65 M − Nd − − +bi[123/200] +[123/200] 2 abnormalities
66 M nd + − − − − 1 abnormality
67 UM + − +[181/200] − − − 2 abnormalities
68 M − − − − +mono[174/200] − Normal
69 UM + + − +[59/200] +mono[10/200]/bi[55/200] − Complex
70 M − − − − − +[125/200] 1 abnormality
71 UM − − +[193/200] − − − Complex
72 UM + + +[186/200] − − − Complex
73 M − − +[195/200] − +bi[192/200] − Complex
74 UM + − +[33/200] − − +[110/200] Failure
75 M + − − − +mono[183/200] − nd
76 UM + − − − +mono[140/200] − Complex
77 UM − − − +[121/200] +mono[122/200] − Normal
78 UM + + − +[169/200] +mono[173/200] − 2 abnormalities
(Continued)
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Table 2. (Continued)
Patient Number IGHV Mutational Status ZAP70 CD38 FISH Karyotype
Del 17p Del 11q Del 13q Trisomy 12
79 UM + − − − − +[146/200] nd
80 UM + + − − +mono[43/200] − Complex
IGHV mutational status homology  98%: M, mutated; UM, unmutated. ZAP70 is considered negative when the ratio (R) of mean ﬂuorescence of T
lymphocytes/mean ﬂuorescence of CLL B lymphocytes  12. ZAP70 is considered positive if R  10, and “grey zone” if 10 < R < 12. CD38 is considered
positive when the percentage of positive leukemic cells is 30%. FISH: score of interphasic cells with an abnormality. Complex karyotype is 3
chromosomal abnormalities. bi, biallelic; Del, deletion; mono, monoallelic; nd, not done.
doi:10.1371/journal.pmed.1001796.t002
Table 3. CLL patients with TP53 abnormalities.
Patient Number Del 17p (FISH) P53 Functional Assessment TP53 Mutational Status
25 23% [46/200] Dysfunctional c.536A>G/p.H179R (exon 5)
30 53% [107/200] Dysfunctional c.425C>G/p.P142R (exon 5) + c.665C>T/p.P222L (exon 6)
53 89% [178/200] Dysfunctional Unmutated (exons 5–8)
59 17% [34/200] Dysfunctional c.Del790–792CTA/p.Del264L (exon 8)
62 97% [195/200] Dysfunctional c.417G>T/p.V173L (exon 5)
67 90% [181/200] Dysfunctional c.524G>A/p.R175H (exon 5)
71 96% [193/200] Dysfunctional c.184G>T, p.E62X (exon 4)
72 93% [186/200] Dysfunctional p.R273H (exon 8)
73 97% [195/200] Dysfunctional c.818G>A, p.R273H (exon 8)
74 16% [33/200] Dysfunctional c.536C>T/p.H179Y (exon 5)
79 0% [0/200] Dysfunctional IVS9+2A>G (intron 9) (homozygous)
The assessment of the functional status of P53 in CLL cells was based on induction of P21 and P53 protein expression using etoposide and nutlin-3a
[39]. The detection of TP53 mutations was performed as described in Methods. FISH: score of interphasic cells with an abnormality. Del, deletion.
doi:10.1371/journal.pmed.1001796.t003
Table 4. Transcript expression levels of Ca2+-related signaling molecules.
Endogenous Reference mRNA Expression in CLL versus Normal B Cells
GUSB PLCB1 0.6
PLCB2 1.5
PLCB3 1.2
PLCB4 1.0
PLCG1 3.3
PLCG2 1.0
ITPR1 0.5
ITPR2 1.3
ITPR3 0.9
RYR1 1.0
RYR2 1.0
RYR3 1.0
STIM1 1.0
(Continued)
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Editors’ Summary
Background
Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia (cancer
of the white blood cells). It accounts for about a third of all adult leukemias, and about one
in 200 people will develop CLL during their lifetime, usually in old age. White blood cells
(including T and B lymphocytes) are made by the bone marrow (the soft center of certain
bones in the body) and help the body fight infections. Leukemia begins when a bone mar-
row cell acquires genetic changes (mutations and chromosomal abnormalities) that make
it grow and develop abnormally. Over time, the abnormal cells accumulate in the bone
marrow, blood, and lymphoid organs (lymph nodes and spleen) (malignant B lympho-
cytes accumulate in the case of CLL) and stop the marrow producing healthy blood cells.
CLL does not usually cause any symptoms during its early stages and is often diagnosed as
a result of a routine blood test. Some patients, however, develop painless swellings in the
lymph nodes in the neck, armpit, or groin. Other symptoms of CLL include tiredness, fre-
quent infections, and weight loss. Treatments for CLL, which are not given unless symp-
toms develop, include chemotherapy, immunotherapy, and targeted therapies, which
attack cancer cells without harming normal cells.
WhyWas This Study Done?
CLL develops very slowly, and people with CLL usually live for many years after their diag-
nosis. However, there is no cure for CLL, and treatment fails in up to a quarter of patients
because resistance to chemotherapy develops. The outlook (prognosis) is particularly bad
for patients whose cancer cells contain a dysfunctional TP53 gene (TP53 encodes a protein
that normally regulates cell division and cell death). Although some new therapies have re-
cently been approved in the US and Europe, additional approaches to the treatment of
CLL are still needed. One potential target for new treatments is the cell surface receptor
CD47. In CLL cells, activation of CD47 by a small fragment (peptide) of thrombospondin-
1 (a protein that binds to CD47) called 4N1K rapidly induces caspase-independent pro-
grammed cell death (PCD), a type of cell death in which the cell uses specialized cellular
machinery to kill itself. (PCD normally controls cell numbers and eliminates cells that
threaten an animal’s survival, but cancer cells often resist PCD.) Unfortunately, peptides
are usually degraded quickly in the human body, which limits their usefulness as therapeu-
tic agents. Here, therefore, the researchers investigate whether PKHB1, a variant of 4N1K
designed to be stable in the body (a “serum-stable” agonist peptide), might provide a new
approach to the treatment of CLL.
What Did the Researchers Do and Find?
The researchers tested the ability of PKHB1 to kill malignant CLL B lymphocytes grown
from blood samples collected from 80 patients with CLL. PKHB1 efficiently killed these
cells, including those from individuals with a dysfunctional TP53 gene but, importantly,
did not kill either normal T and B lymphocytes collected from healthy donors or the resid-
ual normal T and B lymphocytes present in the patient samples. Genetic and molecular
analyses undertaken by the researchers indicated that the differential response of normal
and leukemic B lymphocytes to PKHB1 was the result of sustained activation of a protein
called phospholipase C gamma-1 (PLCγ1) in the malignant CLL B lymphocytes. Other
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experiments showed that PLCγ1 activation drove the induction of a new PCD pathway (a
calcium-mediated, caspase-independent pathway) that was not down-regulated by surviv-
al stimuli provided by the lymphocyte microenvironment. Finally, the researchers report
that injection of PKHB1 reduced the tumor burden in a mouse model of CLL.
What Do These Findings Mean?
Taken together, these findings suggest that serum-stable CD47 agonist peptides represent
a potential new treatment for CLL that could circumvent the problem of chemotherapy re-
sistance and eliminate malignant CLL B lymphocytes while sparing residual normal B and
T lymphocytes. These findings also demonstrate that PKHB1, the serum-stable CD47 ago-
nist peptide tested in this study, directly induces a novel PCD pathway, thereby overcom-
ing the innate avoidance of apoptosis by CLL cells. Before peptide-based strategies for the
treatment of CLL can enter clinical trials, however, further studies are needed to develop
peptides with increased stability and increased ability to bind to and activate CD47. More-
over, because the mouse CLL model used here incompletely recreates the development of
CLL in people, the effectiveness and safety of this pioneer approach needs to be tested
much more rigorously in animals before any clinical trials are initiated.
Additional Information
Please access these websites via the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001796.
• The US National Cancer Institute provides information about cancer and how it
develops, about targeted cancer therapies, and about CLL and its treatment (in English
and Spanish)
• Cancer Research UK, a not-for-profit organization, provides general information about
cancer and how it develops and detailed information about CLL
• The UK National Health Service website also provides information about CLL
• The American Society for Hematology provides general information about blood cancer
and detailed information about leukemia, including CLL
• The French Society for Hematology provides general information about CLL (in
French)
• The not-for-profit Force Hemato organization provides general information about lym-
phoproliferative disorders and resources for patients and families (in French)
• The not-for-profit organization HealthTalkOnline provides personal stories about living
with CLL
• Wikipedia provides information about programmed cell death and about CD47 (note
that Wikipedia is a free online encyclopedia that anyone can edit; available in seve
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